Recce Pharmaceuticals is positioned to gain from a new US$66.9 billion US government strategy focused on combating pandemics, antimicrobial resistance, and biological threats. The plan prioritizes broad-spectrum antimicrobials with US$4.46 billion allocated for developing treatments against drug-resistant infections, aligning closely with Recce's synthetic anti-infective technology. Recce's lead candidate, RECCE® 327, shows activity against key pathogens identified in the strategy, supported by existing US defense collaborations and grants. While the company is optimistic about opportunities from this initiative, it cautions that additional funding is not guaranteed.
Arbitrum surged 45.95% to $0.1928, leading the day's top crypto gainers due to increased investor confidence in Ethereum layer-2 scaling solutions that reduce costs and improve speed. Other notable gainers included Pons, Uniswap, PancakeSwap, and Eth...
Resideo's Senior Vice President, Mehta, recently purchased 10,928 shares of the company's stock through a direct purchase valued at $226,000. This insider buying can signal confidence in the company's future prospects and may influence investor senti...
Arthur Hayes, co-founder of BitMEX, purchased 244,406 UNI tokens worth $1.73 million through an OTC deal with Flowdesk, avoiding market impact. This sizable buy is notable as there is no current governance proposal or upgrade driving the purchase, in...
Greg Abel, Warren Buffett's successor, invested heavily in a single stock, spending $4.5 billion last quarter and at least $3.3 billion this quarter. This large purchase indicates strong confidence in the stock's future prospects. Investors may view ...
Shiba Inu's futures market has seen a 19.28% surge in open interest, with over 10.74 trillion SHIB tokens committed to derivatives trading. This surge follows a nearly 5% price increase, helping SHIB maintain its key $0.000005 level despite recent co...
